Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etheno-Nadp is a synthetic, intrinsically fluorescent analog of nicotinamide adenine dinucleotide phosphate (NADP). It is classified as a small molecule and is primarily used in experimental and research settings rather than as an approved pharmaceutical agent. The etheno modification introduces a fluorescent moiety into the NADP structure, making it useful for biochemical assays that require sensitive detection of NADP-dependent enzymatic reactions or binding events. Its mechanism of action involves acting as a cofactor analog in studies of enzymes that normally utilize NADP, allowing researchers to track enzyme activity or binding through fluorescence-based methods. There are no known clinical indications or therapeutic uses for Etheno-Nadp; its applications are limited to laboratory research[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Etheno-Nadp.